Bleeding on menopause hormone therapy: expected pattern or reason to call?

Light spotting can occur when menopausal hormone therapy (MHT or HRT) starts or a regimen changes, but unexpected, persistent or later new bleeding should be reported to the prescribing clinician. “On HRT” does not identify a harmless cause. A scheduled withdrawal bleed on a cyclic regimen, irregular bleeding on a continuous regimen, and bleeding after menopause without a planned cycle are different stories. The clinician needs the regimen, timing, uterine status and other risk information to decide what evaluation is appropriate.¹²³

Describe the pattern before trying to explain it

An estrogen-only patch, a continuous estrogen–progestogen combination and a sequential regimen do not create the same expected bleeding pattern. Some sequential plans are designed around predictable withdrawal bleeding. A continuous plan may have early irregular bleeding as the body adjusts, but the plan is not a license to ignore bleeding that is unexpected or continues. If a person has no uterus, vaginal bleeding has a different starting explanation from bleeding in someone with an intact uterus. The product names and dates matter more than the generic phrase “hormone replacement.”²

The British Menopause Society’s guidance illustrates why prescribers ask about when therapy began or changed, the exact progestogen schedule and adherence, and endometrial-cancer risk factors. It is UK guidance, not a Florida testing protocol; its diagnostic thresholds should not be copied into an American appointment. It does show that a useful history is more precise than “I spotted on HRT.”²

Early spotting and evaluation are not opposites

It is reasonable for a clinician to explain that a newly started regimen can be accompanied by spotting. It is not reasonable for an online article to decide that a specific reader’s bleeding is “just adjustment.” British Menopause Society guidance separates early bleeding after a start or change from patterns needing investigation, while FDA patient guidance says to tell a healthcare provider about bleeding after menopause. A possible adjustment pattern and a clear follow-up plan can coexist; neither lets a website dismiss an individual’s bleeding.²³

The April 2026 ACOG update on postmenopausal bleeding is also important. It changed the older shorthand that a reassuring ultrasound measurement alone could generally close the question. ACOG says most people presenting for initial evaluation of postmenopausal bleeding should have both ultrasound and tissue sampling. That does not mean every person with a small episode must choose tests themselves, or that an HRT user can apply a single numerical cutoff at home. The clinician decides how the updated guidance fits the actual situation.¹

Symptoms that are heavy, worsening, or accompanied by faintness, severe pain or other urgent concerns should prompt timely medical attention rather than waiting for a routine cosmetic or wellness follow-up. The article cannot determine the cause or urgency for an individual.

The five-line note that helps a prescriber

Before contacting the practice, record the first and most recent day of bleeding; whether it was spotting or a flow; whether it coincided with a planned hormone cycle; the exact estrogen and progesterone/progestin products, routes and changes; and whether the uterus is present. Include missed doses and other medicines. A simple dated note is more useful than trying to estimate a cause from color alone.

Ask who will review the information and what response time to expect. If the service is managed by a wellness clinic, clarify who is responsible for gynecologic evaluation and how a referral works. An invitation to “just increase progesterone” without confirming the product, uterine status and reason for bleeding is not an adequate substitute for assessment. The progesterone-versus-progestin guide explains why the exact molecule and formulation matter; the progesterone-cream guide addresses a different, specific claim about endometrial protection.

Treat follow-up ownership as part of the hormone plan

Before beginning treatment, a provider should be able to explain which bleeding pattern, if any, is expected for the proposed regimen and how unexpected bleeding is handled. That is a useful provider-selection question even for someone with no current symptoms. A practice that can name a prescriber, response channel and gynecologic referral route offers a more complete plan than one that only dispenses a product.

Use Treomark’s hormone-therapy discovery page to identify a relevant consultation, then ask the clinician to put the regimen and follow-up process in plain language. The goal is not to avoid hormone therapy because bleeding might occur; it is to know what a change means for the plan and who will evaluate it.